Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04318717 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
A Phase 2 study of Mucosal Melanoma of the Head and Neck, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04318717 is a Phase 2 study of Mucosal Melanoma of the Head and Neck that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04318717, a Phase 2 study of Mucosal Melanoma of the Head and Neck, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Hypofractionated radiation therapy
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-05-29 |
| Est. Completion | 2032-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04318717
The ClinicalTrials.gov registry entry for NCT04318717 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mucosal Melanoma of the Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04318717 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04318717 about?
NCT04318717 is a clinical study titled "Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma". This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with his...
What is the current status of trial NCT04318717?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2020-05-29. Estimated completion is 2032-07-31.
What conditions does trial NCT04318717 study?
This clinical trial studies the following conditions: Mucosal Melanoma of the Head and Neck.
What interventions are being tested in trial NCT04318717?
The interventions under investigation include: Pembrolizumab (DRUG), Hypofractionated radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04318717?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04318717 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.